Objective: To evaluate final adult height after recombinant growth hormone (GH) treatment in girls with Turner syndrome (TS) and predictors of their growth response. Method: Seventy-four patients with Turner syndrome who treated with GH and reached adult height were enrolled in this study. To determine final height gain, we assessed the difference between the final height standard deviation score (SDS) and height SDS at start of treatment. In addition, the difference between the final height and predicted adult height at start of treatment was assessed. Results: GH therapy started at the mean age of 8.91±3.71 years in Turner patients. The mean duration of GH therapy was 6.42±3.03 years. Mean height at start of treatment was 116.54±16.66 cm, and height SDS was -3.73±1.48. Patients who treated GH reached an adult height of 152.08±4.67 cm, and final height SDS was -1.96±1.50. Final height SDS was found to have a positive significant correlation with height SDS at start of treatment ( P0.001) and mid-parental Height SDS ( P0.001). In addition, the final height is influenced by confounding variables of the duration of GH therapy, chronological age at start of treatment and karyotype. Height SDS gain was found to have a positive significant correlation with height SDS at start of treatment ( P0.001), start of treatment chronological age ( P0.007) and the duration of GH therapy ( P0.015). Conclusion: Our data demonstrate that GH therapy seems effective in improving final height SDS and height SDS gain in Turner syndrome. And early intervention of GH in patients with TS seems to be necessary for final height gain.